Skip to main content
Premium Trial:

Request an Annual Quote

N-of-One to Provide Decision Support for Guardant360 Cell-Free DNA Test

NEW YORK (GenomeWeb) – Diagnostics developer Guardant Health has inked a deal with molecular data interpretation firm N-of-One to provide decision support services for its Guardant360 test.

The diagnostic uses next-generation sequencing to analyze cell-free DNA, tumor fragments shed into the blood at low concentrations. The test can be used to gauge genetic alterations driving various tumor types and can be used by doctors to inform personalized medicine strategies for patients or guide them to clinical trials.

The companies did not disclose the financial terms of their deal.

Guardant announced the commercial launch of Guardant360 in February. In April, Guardant, in partnership with Khosla Ventures, Pejman Mar, and Sequoia Capital, raised $30 million in Series B financing to accelerate and expand commercialization efforts behind the test.

In a statement, Chris Cournoyer, CEO of N-of-One, suggested that the company hopes its data interpretation services will help Guardant scale its test volumes in a cost-effective fashion.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.